摘要
目的 检测成年T细胞急性淋巴细胞白血病（T-ALL）患者Ikaros6的表达,并探讨其临床意义.方法 提取成年T-ALL患者初发时骨髓单个核细胞的RNA,反转录为cDNA,采用反转录-聚合酶链反应（RT-PCR）扩增技术进行检测,测序进一步确定结果,并结合患者临床资料分析临床特点及其预后.结果 74例初发成年人T-ALL中,Ikaros6阳性率为21.6％（16例）,另外阳性患者较阴性患者更易发生髓外浸润（x2=4.084,P=0.043）,且外周血白细胞计数高（103.15×109/L比15.60×109/L）、贫血更严重（血红蛋白75.95 g/L比107.00 g/L）和血小板计数低（26.0×109/L比67.0×109/L）,但差异均无统计学意义（均P＞ 0.05）.Ikaros6阳性患者生存期短和具有高复发风险.结论 Ikaros6在成年人T-ALL中表达率较高,阳性患者具有外周血白细胞计数高和易出现髓外浸润等临床特点,预后差,具有高复发风险.Ikaros6可考虑作为成年人T-ALL分层治疗或预后判断的分子指标.
Objective To investigate the expression and prognostic value of Ikaros6 in adult T-cell acute lymphoblastic leukemia（T-ALL） patients.Methods The RNA was extracted from mononuclear cells of bone marrow in 74 adult T-ALL patients.The expression of Ikaros6 was examined by reverse transcription-PCR,and the results were confirmed by sequencing.Clinical features and prognosis were analyzed based on clinical data.Results In 74 T-ALL patients,the incidence rate of Ikaros6 was 21.6 % （16/74）.Extramedullary infiltrations were occurred often （x2 =4.084,P =0.043）,had higher WBC （103.15 × 109/L vs 15.60×109/L,t =0.214,P =0.831）,more severe anemia （75.95 g/L vs 107.00 g/L,t =1.504,P =0.142） and lower platelet count （26.0×109/L vs 67.0×109/L,t =1.421,P =0.164） in patients with Ikaros6 positive.Meanwhile Ikaros6-positive patients had inferior survival and were increased risk of relapse as compared with the Ikaros6-negative patients.Conclusions The incidence of Ikaros6 is high in adult T-ALL patients.Ikaros6-positive patients are more likely to have extramedullary infiltration and higher WBC,meanwhile they had inferior survival and increased risk of relapse.Thus Ikaros6 may be served as a valuable factor for risk stratification and prognosis evaluation in adult T-ALL patients.
出处
《白血病．淋巴瘤》
CAS
2014年第2期84-87,91,共5页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金（81200382、81270600、81025011）
